Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corvus Pharmaceuticals, Inc. - Common Stock (NQ:CRVS)

25.98 +3.83 (+17.27%)
Streaming Delayed Price Updated: 1:35 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corvus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer ↗
Oppenheimer has initiated coverage on Corvus Pharmaceuticals Inc (NASDAQ: CRVS) with an Outperform rating and a  
Via Benzinga
News headline image
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings for Corvus Pharma ↗
 
Via Benzinga
News headline image
Corvus Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Mobilicom Limited (NASDAQ: MOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the... 
Via Benzinga
News headline image
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. 
Via Benzinga
News headline image
Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2 ↗
Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics. 
Via Talk Markets
News headline image
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 High-Potential Penny Stocks to Buy Now ↗
When it comes to penny stocks to buy now, be aware of the risks. While some of these little guys can rocket, some will be duds. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
News headline image
Why Are Corvus Pharmaceuticals Trading Higher Today ↗
In its Q1 earnings release, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) revealed updated data from the Phase 1/1b trial evaluating single-agent therapy with CPI-818 in patients with  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
7 High-Potential Penny Stocks in the Biotech Sector ↗
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
News headline image
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The 3 Best Biotech Stocks Under $1 to Buy for April ↗
While risky, here are some of the best biotech stocks under $1, with solid catalysts, investors may want to consider. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad... 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.